NCT06601465 (CONVERGE-HF) is a Phase 2 clinical trial of Vericiguat in Heart Failure, sponsored by University of Alberta.

Who is sponsoring NCT06601465?

NCT06601465 is sponsored by University of Alberta.

What drugs are being tested in NCT06601465?

Interventions in NCT06601465: Vericiguat.

What condition does NCT06601465 study?

NCT06601465 studies Heart Failure, Cognitive Impairment.

Is NCT06601465 still recruiting?

NCT06601465 is currently recruiting now. Last updated 30 July 2025.

Last reviewed 2025-07-30 · How we verify

NCT06601465: CONVERGE-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure

Recruiting now Phase 2 Last updated 30 July 2025

What this trial tests

Phase 2 trial testing Vericiguat in Heart Failure in 120 participants. Currently enrolling.

Timeline

3 June 2025

Primary endpoint
1 July 2026

1 May 2027

Quick facts

Lead sponsor	University of Alberta
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	3 June 2025
Primary completion	1 July 2026
Estimated completion	1 May 2027
Sites	4 locations across Canada

Drugs / interventions tested

Vericiguat (VERICIGUAT) — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

University of Alberta

Who can join

18 and older, any sex, with Heart Failure or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in the lateral ventricular volumes.
Time frame: 26 weeks
To determine whether in patients with heart failure and mild-to-moderate cognitive impairment, the 26 weeks of treatment with sGC stimulator, vericiguat versus standard of care lead to greater reduction (or smaller increase) in lateral ventricular volume in brain MRI as a proxy for the preservation of brain microvasculature and preventing brain tissue loss.

Sponsor's own description

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vericiguat

Trials testing the same drug.

NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting
NCT07047547 — A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure · NA · recruiting
NCT06415227 — The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris · Phase 2 · not yet recruiting
NCT06812546 — Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction · Phase 4 · not yet recruiting
NCT06671990 — The CardioMEMS Vericiguat Heart Failure Trial · Phase 4 · not yet recruiting

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06601465 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 30 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06601465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing